Xu 2016.

Methods	Study design: Randomised clinical trial Study duration: December 2010 to July 2012 Duration of follow‐up: 3 years Setting: Hospital
Participants	Age (mean ± SD): TACE + RFA: 52.9 ± 5.4 years; TACE alone: 53.4 ± 6.8 years Male (n/total): TACE + RFA: 28/38; TACE alone: 27/34 Child‐Pugh Class (patients): Class A: TACE + RFA: 20; TACE: 19 Class B: TACE + RFA: 18; TACE: 15
Interventions	TACE + RFA group (n = 38): TACE: Chemotherapeutic drugs: 5‐fluorouracil, theprubicin, and epirubicin RFA: The interval between TACE and RFA was 2 weeks. Output power of 50‐100 W TACE group (n = 34): Chemotherapeutic drugs: 5‐fluorouracil, theprubicin, and epirubicin
Outcomes	Serum level of AFP Liver function Tumour response, measured by contrast‐enhanced CT or MRI; measured at 3 months after treatment 1‐, 2‐, and 3‐year survival rates
Notes	Country of study: China Source of funding: Qinhuangdao Science and Develoment Funding There was insufficient information available to satisfactorily determine the method of randomisation and the study data could not be verified. We have attempted to contact the study authors for more information, but so far, we have not been successful in doing this.